Attributes | Values |
---|
rdf:type
| |
Description
| - Background: Defects in the p53 gene predispose B CLL patients for an inferior outcome, particularly a resistance to treatment by conventional chemotherapeutics. Very little data exist, however, about the efficacy of monoclonal antibody rituximab on B CLL cells bearing p53 abnormalities. One reason for that might be a methodological: rituximab alone does not have virtually any effect on the viability of B CLL cells when cultivated in vitro, unless an active human plasma is added. After that, however, the cells are quickly lysed by complement, what is a process independent on p53. Aims: We used an in vitro system (not containing the active human plasma) to monitor a rituximab activity on B CLL cells with p53 inactivation in relation to subsequently used nucleoside analog fludarabine, which demonstrably acts through the p53 in B CLL cells.
- Background: Defects in the p53 gene predispose B CLL patients for an inferior outcome, particularly a resistance to treatment by conventional chemotherapeutics. Very little data exist, however, about the efficacy of monoclonal antibody rituximab on B CLL cells bearing p53 abnormalities. One reason for that might be a methodological: rituximab alone does not have virtually any effect on the viability of B CLL cells when cultivated in vitro, unless an active human plasma is added. After that, however, the cells are quickly lysed by complement, what is a process independent on p53. Aims: We used an in vitro system (not containing the active human plasma) to monitor a rituximab activity on B CLL cells with p53 inactivation in relation to subsequently used nucleoside analog fludarabine, which demonstrably acts through the p53 in B CLL cells. (en)
|
Title
| - Rituximab Senzitizes B-CLL Cells with Inactived p53 to fludarabine
- Rituximab Senzitizes B-CLL Cells with Inactived p53 to fludarabine (en)
|
skos:prefLabel
| - Rituximab Senzitizes B-CLL Cells with Inactived p53 to fludarabine
- Rituximab Senzitizes B-CLL Cells with Inactived p53 to fludarabine (en)
|
skos:notation
| - RIV/00216224:14310/06:00019160!RIV10-MZ0-14310___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| - Pospíšil, Zdeněk
- Chumchalová, Jitka
- Pospíšilová, Šárka
- Brychtová, Yvona
- Kuglík, Petr
- Doubek, Michael
- Mayer, Jiří
- Šmardová, Jana
- Trbušek, Martin
- Čejková, Soňa
|
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216224:14310/06:00019160
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - B-CLL p53 rituximab fludarabine in vitro (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...iv/tvurceVysledku
| - Brychtová, Yvona
- Doubek, Michael
- Kuglík, Petr
- Mayer, Jiří
- Pospíšilová, Šárka
- Pospíšil, Zdeněk
- Trbušek, Martin
- Šmardová, Jana
- Čejková, Soňa
- Chumchalová, Jitka
|
http://localhost/t...ganizacniJednotka
| |